The lacosamide medicine was approved in September for use on its own or alongside other medicines to treat focal-onset seizures. It was previously approved for use in teenagers over 16 years old and adults in Europe.
Jeff Wren, executive vice president of UCB, said: “[The] approval of lacosamide for children aged 4 to 16 is an important step forward for the management of paediatric epilepsy, a condition which can present significant challenges to children and their families.”
The European Medicines Agency had previously found that focal epilepsy in children over 4 years old is similar to that in adults. According to UCB, the approval of their lacosamide medicine was based on data on its effectiveness in adults and safety data in children.
The company added that children with epilepsy may experience side-effects from the medicines currently available for this type of epilepsy. They also added that around 10-29% of children with epilepsy don’t have seizure control with the medicines available at the moment. UCB concluded that this means there is a need for more and new treatment options to help control seizures in children and avoid side-effects.
You may also be interested in…
Royal College of Paediatrics and Child Health starts next Epilepsy12 audit into children’s epilepsy services
The Royal College of Paediatrics and Child Health (RCPCH) is starting a new review into how effective children’s epilepsy services are. This is known as the Epilepsy12 audit and this is the third review of this kind.